The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty

• Published in: Clinical endocrinology (Oxford) Vol. 77; no. 5; pp. 743 - 748
• Main Authors: Park, Hong K., Lee, Hae S., Ko, Jung H., Hwang, Il T., Lim, Jung S., Hwang, Jin S.
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell Publishing Ltd 01.11.2012; Blackwell; Wiley Subscription Services, Inc
• Subjects: Absorptiometry, Photon; Biological and medical sciences; Body Composition - drug effects; Bone Density - drug effects; Child; Endocrinopathies; Female; Fundamental and applied biological sciences. Psychology; Gonadotropin-Releasing Hormone - therapeutic use; Humans; Investigative techniques, diagnostic techniques (general aspects); Medical sciences; Osteoarticular system. Muscles; Puberty, Precocious - drug therapy; Puberty, Precocious - metabolism; Puberty, Precocious - pathology; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Vertebrates: endocrinology; Endocrinopathy; Human; Agonist; Gonadotropin RH; Body composition; Precocious puberty; Hypothalamic hormone; Treatment; Female; Bone mineral density; Hormone releasing factor; Child; Endocrinology
• ISSN: 0300-0664; 1365-2265; 1365-2265
• DOI: 10.1111/j.1365-2265.2012.04418.x

Objective Puberty is a period characterized by growth spurt and rapid change in body composition. The effect of GnRH agonist therapy for central precocious puberty on bone mineral density is unclear. We demonstrated changes in bone mineral density in subjects with central precocious puberty, who were treated with GnRH agonist for more than 3 years. Design The changes in bone mineral density and body compositions were tested with analysis of variance with repeated measures to identify statistical significance over the treatment period. Patients One hundred ninety‐five Korean girls with central precocious puberty were treated with GnRH agonist, and among these subjects, 39 patients were treated for more than 3 years. Measurements Dual‐energy X‐ray absorptiometry was performed on the subjects at the initial evaluation and once yearly thereafter while on the treatment. Results The bone mineral density parameters for chronological age tended to decrease near the mean for the treatment period; however, they increased significantly for bone age excluding bone mineral apparent density. An increment of the BMI was not significant for the chronological age. Conclusions Three‐year treatment with GnRH agonist in central precocious puberty patients did not impair bone maturation. GnRH agonist could be effectively commenced in girls with precocious puberty from an early age.